Jiang, C. Y., Jindal, T., Epstein, I. B., Nguyen, C. B., Nizam, A., Bakaloudi, D. R., … Campbell, M. T. (2024). Efficacy of erdafitinib in FGFR2/3-altered metastatic urothelial cancer including patients with CDK2NA/B or MTAP loss: Analysis of UNITE study. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 42).

Jiang, Cindy Y., Tanya Jindal, Ilana B. Epstein, Charles B. Nguyen, Amanda Nizam, Dimitra Rafailia Bakaloudi, Amy K. Taylor, et al. “Efficacy of erdafitinib in FGFR2/3-altered metastatic urothelial cancer including patients with CDK2NA/B or MTAP loss: Analysis of UNITE study.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 42, 2024.

Jiang CY, Jindal T, Epstein IB, Nguyen CB, Nizam A, Bakaloudi DR, et al. Efficacy of erdafitinib in FGFR2/3-altered metastatic urothelial cancer including patients with CDK2NA/B or MTAP loss: Analysis of UNITE study. In: JOURNAL OF CLINICAL ONCOLOGY. 2024.

Jiang, Cindy Y., et al. “Efficacy of erdafitinib in FGFR2/3-altered metastatic urothelial cancer including patients with CDK2NA/B or MTAP loss: Analysis of UNITE study.” JOURNAL OF CLINICAL ONCOLOGY, vol. 42, no. 16, 2024.

Jiang CY, Jindal T, Epstein IB, Nguyen CB, Nizam A, Bakaloudi DR, Taylor AK, Milowsky MI, Shah S, Hoimes CJ, Bilen MA, Zakharia Y, Emamekhoo H, Grivas P, Gupta S, Bellmunt J, Alva AS, Koshkin VS, Alhalabi O, Campbell MT. Efficacy of erdafitinib in FGFR2/3-altered metastatic urothelial cancer including patients with CDK2NA/B or MTAP loss: Analysis of UNITE study. JOURNAL OF CLINICAL ONCOLOGY. 2024.